UPDATE - Canaccord Genuity Initiates Coverage on GenMark Diagnostics (GNMK) with a Buy; Addressing Key Needs of Laboratories
Tweet Send to a Friend
UPDATE - Canaccord Genuity initiates coverage on GenMark Diagnostics (NASDAQ: GNMK) with a Buy. PT $8.
Canaccord analyst says, "Our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Canaccord analyst says, "Our ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
